Evidence map›Paper›PMID 40546961›Full record

ReviewiScience2025

Diversifying the solar photovoltaic supply chain to secure Europe's energy and climate roadmap and sovereignty.

Marie-Ann Evans, Pierre-Philippe Grand, Julien Dupuis

Abstract readReview
In one paragraph

Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marie-Ann EvansEDF Lab Paris-Saclay, Palaiseau, France.
Pierre-Philippe GrandEDF Lab Paris-Saclay, Palaiseau, France.
Julien DupuisEDF Lab Paris-Saclay, Palaiseau, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Europe relies on solar photovoltaic (PV) as one of the main energy sources in its climate roadmap. Europe has been a pioneer and leader in PV production, and the installation targets are continually increasing via Renewable Energy Directive revisions. However, over the last 15 years, most of the manufacturing capacities of solar PV modules and upstream components have been offshored to China where they have been largely upscaled and upgraded. These so-called gigafactories have led to significant cost reductions for PV modules and have supported the uptake of solar energy worldwide, China itself becoming the market leader. Nevertheless, facing successive energy, sanitary, and political crises, Europe has been impacted by the vulnerability of globalized supply chains and is bringing sovereignty back to the center of debate. Its recent Industrial Green Deal especially focused on strategic technologies such as PV. Indeed, the overwhelming domination of China in PV products puts the sector supply chain at high risk of disruption. This could be critical in the long term when the time comes for repowering a dominant infrastructure and much earlier once the current thermal power plants are decommissioned to be replaced by PV. Moreover, the unavailability of key components could impede the proper operation of installed PV, threatening energy security. One of the sovereignty drivers is to reshore some manufacturing capacities in Europe, but, as seen in the United States with the Inflation Reduction Act consequences, reindustrializing comes at a significant cost. Based on a detailed bottom-up PV production model to quantify the various cost items, this article discusses strategies for Europe to diversify the supply chain of PV, including rebuilding a minimum share of factories and also developing strategic partnerships, to pursue its energy transition while maintaining affordable costs for consumers.

Indexed as

Energy policyEngineering

Identifiers

PMID40546961
PMCPMC12182299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.